NCT06353386 2026-03-13
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT01116648 2026-03-05
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02264678 2026-02-20
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
AstraZeneca
Phase 1/2 Active not recruiting
NCT03317392 2026-02-19
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting